시장보고서

상품코드

1771463

세계의 신경질환 임상시험 시장 : 시장 규모, 점유율, 동향 분석 - 페이즈별, 시험 설계별, 적응증별, 밸류체인별, 지역별, 부문별 예측(2025-2030년)

Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경질환 임상시험 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 신경질환 임상시험 시장 규모는 2030년까지 84억 2,000만 달러에 달할 전망이며, 2025-2030년 CAGR 6.39%로 성장할 것으로 추정됩니다.

이는 주요 제약회사가 신경과학 분야에서 혁신적인 임상시험을 실시하고 있는 것, 미국 국립신경질환 및 뇌졸중연구소(NINDS)로부터의 정부 보조금이 증가하고 있는 것, 세계적으로 신경질환의 유병률이 높은 것이 주요 요인입니다.

신경과학은 건전한 투자를 계속 받고 있습니다. 예를 들면, 2022년 11월, NRG Therapeutics사는, 근위축성 측삭 경화증(ALS)이나 파킨슨병 등의 신경 변성 질환을 치료하는 미토콘드리아 치료약의 개발을 위해, 1,830만 달러의 시리즈 A 자금을 조달했습니다. 향후도 같은 대처가 채용되는 것으로, 시장의 성장이 기대됩니다.

전 세계적으로 상당수의 사람들이 신경 질환으로 고통받고 있습니다. 예를 들면, Parkinson's Foundation의 통계에 의하면, 매년 6만명의 미국인이 PD로 진단되어, 전세계적으로 1,000만 명 이상의 사람들이 이 병과 공존하고 있습니다. 간질에 관해서는, WHO는 전세계적으로 6,500만 명 이상이 간질에 감염되고 있다고 발표하고 있습니다. 이 질환은 중저소득 국가에서 가장 많고 뇌전증 환자의 80.0%를 차지하고 있습니다. 높은 신경질환 유병률이 임상시험 수요를 끌어올려 시장을 지탱할 것으로 기대되고 있습니다.

신경학은 임상시험이 수행되는 주요 분야 중 하나로 여겨지고 있습니다. Pharma R&D Annual Review에 따르면 2021년 신경질환 임상시험은 임상시험이 주로 진행되는 세 번째 분야였습니다. Pharma R&D Annual Review에 따르면 신경학 영역에서는 2,900개 이상의 의약품이 시험 중이었고 2022년에는 3,200개 이상의 의약품이 시험 중이었습니다. 신경 영역에서 임상 시험을 시작하는 약제의 증가는 팬데믹 이후의 시장을 뒷받침할 것으로 예상됩니다.

신경질환 임상시험 시장 : 분석 개요

페이즈별로는 페이즈 II가 시장을 독점하여 2024년에는 42.14%의 최대 매출 점유율을 차지했습니다. 신경질환 임상시험의 대부분은 현재 2단계에 있으며, 이것이 이 부문 시장을 지탱하고 있습니다.
시험 설계별로는 인터벤셔널 세분화이 2024년에 최대 시장 매출 점유율을 차지했습니다. 이 시험 디자인으로 실시되는 신경질환 임상시험의 수가 많은 것이, 이 부문 시장의 성장을 촉진하고 있습니다.
적응증별로는 헌팅턴병 분야가 예측 기간 중에 높은 CAGR을 나타낼 것으로 예측되고 있습니다. 이는 헌팅턴병에 사용되는 의약품에 대한 수요가 세계적으로 높다는 사실에서 기인합니다.
북미가 시장을 독점하여 2024년에는 46.96%의 매출 점유율을 차지했습니다. 신경질환 유병률이 상승하면서 임상시험에 많은 기업이 참여하고 있는 것이 이 지역 시장을 견인하고 있습니다. 이것들이 높은 시장 점유율의 주된 이유입니다.

시장 연관 전망
- 상위 시장 전망
- 관련 및 부수 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 시장 기회
- 시장의 과제
기술 상황
가격 모델 분석
연구개발비 분석(2018-2024년)
임상시험 건수 분석(2024년)
시장 분석 도구
- Porter's Five Forces 분석
- SWOT 분석에 의한 PESTEL
- COVID-19의 영향 분석

제4장 신경질환 임상시험 시장 : 위상별 추정 및 동향 분석

신경질환 임상시험 시장 : 단계별 부문 대시보드
신경질환 임상시험 시장 : 단계별 변동 분석
페이즈별(2018-2030년)
페이즈 I
페이즈 II
페이즈 III
페이즈 IV

제5장 신경질환 임상시험 시장 : 시험 설계별 추정 및 동향 분석

신경질환 임상시험 시장 : 시험 설계별 부문 대시보드,
신경질환 임상시험 시장 : 시험 설계별 변동 분석
시험 설계별(2018-2030년)
개입적
관찰적
확장 액세스

제6장 신경질환 임상시험 시장 : 적응증별 추정 및 동향 분석

신경질환 임상시험 시장 : 적응증별 부문 대시보드
신경질환 임상시험 시장 : 적응증별 변동 분석
적응증별(2018-2030년)
신경질환 임상시험 시장 : 적응증별 부문 대시보드
신경질환 임상시험 시장 : 적응증별 변동 분석
적응증별(2018-2030년)
알츠하이머병
우울증(MDD)
파킨슨병(PD)
간질
뇌졸중
외상성 뇌손상(TBI)
근위축성 측삭 경화증(ALS)
헌팅턴병
근육의 재생
기타

제7장 신경질환 임상시험 시장 : 시험 설계별, 적응증별 추정 및 동향 분석

신경질환 임상시험 시장 : 시험 설계별 및 적응증별 부문 대시보드
신경질환 임상시험 시장, 시험 설계별 및 적응증별 변동 분석
시험 설계별(2018-2030년)
알츠하이머병
- 알츠하이머병 개입
- 알츠하이머병 관찰
- 알츠하이머병 확대 액세스
우울증(MDD)
- 우울증(MDD) 개입
- 우울증(MDD) 관찰
- 우울증(MDD) 확대 액세스
파킨슨병(PD)
- 파킨슨병(PD) 개입
- 파킨슨병(PD) 관찰
- 파킨슨병(PD) 확대 액세스
간질
- 간질 개입
- 간질 관찰
- 간질 확대 액세스
뇌졸중
- 뇌졸중 개입
- 뇌졸중 관찰
- 뇌졸중 확대 액세스
외상성 뇌손상(TBI)
- 외상성 뇌손상(TBI) 개입
- 외상성 뇌손상(TBI) 관찰
- 외상성 뇌손상(TBI) 확대 액세스
근위축성 측삭 경화증(ALS)
- 근위축성 측삭 경화증(ALS) 개입
- 근위축성 측삭 경화증(ALS) 관찰 연구
- 근위축성 측삭 경화증(ALS) 확대 액세스
헌팅턴병
- 헌팅턴병 개입
- 헌팅턴병 관찰
- 헌팅턴병 확대 액세스
근육의 재생
- 근육 재생 개입
- 근육 재생 관찰
- 근육 재생 확대 액세스
기타
- 기타 개입
- 기타 관찰
- 기타 확장 액세스

제8장 신경질환 임상시험 시장 : 페이즈별, 적응증별 추정 및 동향 분석

신경질환 임상시험 시장 : 페이즈별 및 적응증별 부문 대시보드,
신경질환 임상시험 시장 : 페이즈별 및 적응증별 변동 분석
페이즈별(2018-2030년)
알츠하이머병
- 알츠하이머병 페이즈 I
- 알츠하이머병 페이즈 II
- 알츠하이머병 페이즈 III
- 알츠하이머병 페이즈 IV
우울증(MDD)
- 우울증(MDD) 페이즈 I
- 우울증(MDD) 페이즈 III
- 우울증(MDD) 페이즈 III
- 우울증(MDD) 페이즈 IV
파킨슨병(PD)
- 파킨슨병(PD) 페이즈 I
- 파킨슨병(PD) 페이즈 II
- 파킨슨병(PD) 페이즈 III
- 파킨슨병(PD) 페이즈 IV
간질
- 간질 페이즈 I
- 간질 페이즈 II
- 간질 페이즈 III
- 간질 페이즈 IV
뇌졸중
- 뇌졸중 페이즈 I
- 뇌졸중 페이즈 II
- 뇌졸중 페이즈 III
- 뇌졸중 페이즈 IV
외상성 뇌손상(TBI)
- 외상성 뇌손상(TBI) 페이즈 I
- 외상성 뇌손상(TBI) 페이즈 II
- 외상성 뇌손상(TBI) 페이즈 III
- 외상성 뇌손상(TBI) 페이즈 IV
근위축성 측삭 경화증(ALS)
- 근위축성 측삭 경화증(ALS) 페이즈 I
- 근위축성 측삭 경화증(ALS) 페이즈 II
- 근위축성 측삭 경화증(ALS) 페이즈 III
- 근위축성 측삭 경화증(ALS) 페이즈 IV
헌팅턴병
- 헌팅턴병 페이즈 I
- 헌팅턴병 페이즈 II
- 헌팅턴병 페이즈 III
- 헌팅턴병 페이즈 IV
근육 재생
- 근육 재생 페이즈 I
- 근육 재생 페이즈 II
- 근육 재생 페이즈 III
- 근육 재생 페이즈 IV
기타
- 기타 페이즈I
- 기타 페이즈II
- 기타 페이즈 III
- 기타 페이즈 IV

제9장 신경질환 임상시험 시장 : 밸류체인별 추정 및 동향 분석

신경질환 임상시험 시장 : 밸류체인별 부문 대시보드
신경질환 임상시험 시장 : 밸류체인별 변동 분석
밸류체인별(2018-2030년)
사내
CRO
임상시험 시설 및 임상시설

제10장 신경질환 임상시험 시장 : 지역별 추정 및 동향 분석

시장 대시보드 : 지역별
시장 점유율 : 지역별(2024년, 2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 태국
- 한국
- 호주
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

AJY 25.07.21

Neurology Clinical Trials Market Growth & Trends:

The global neurology clinical trials market size is estimated to reach USD 8.42 billion by 2030, registering a CAGR of 6.39% from 2025 to 2030, according to a new report by Grand View Research, Inc. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.

Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease. The adoption of similar initiatives in the future is expected to support market growth.

A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.

Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.

Neurology Clinical Trials Market Report Highlights:

By phase, the phase II segment dominated the market and accounted for a maximum revenue share of 42.14% in 2024. A majority number of neurology clinical trials are currently in Phase 2, this is supporting the segment market.
By study design, the interventional segment held the largest market revenue share of in 2024. A high number of neurology clinical trials conducted through this study design type is promoting the growth of the segment market.
By indication, the Huntington's disease segment is anticipated to register the significant CAGR over the forecast period. This is largely due to the fact that there is a high demand for the medicines used for Huntington's disease worldwide as there are no medications available for treating this disease.
North America dominated the market and accounted for a revenue share of 46.96% in 2024. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region. These are some of the key reasons for the high market share.

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Study Design
- 1.2.2. Indication
- 1.2.3. Indication by Study Design
- 1.2.4. Indication by Phase
- 1.2.5. Value Chain
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
  - 3.2.1.2. Growing adoption of novel technologies in clinical research
  - 3.2.1.3. Substantial number of CROs providing neurology clinical research services
  - 3.2.1.4. Increasing funding for neurological studies by public organizations
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High cost associated with neurology clinical studies
  - 3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
- 3.2.3. Market Challenges
- 3.2.4. Market Opportunities
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. R&D Spending Analysis (2018-2024)
3.6. Clinical Trial Volume Analysis, 2024
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Force Analysis
- 3.7.2. PESTEL by SWOT Analysis
- 3.7.3. COVID-19 Impact Analysis

Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis

4.1. Neurology Clinical Trials Market, By Phase: Segment Dashboard
4.2. Neurology Clinical Trials Market, By Phase: Movement Analysis
4.3. Neurology Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030 (USD Million)
4.4. Phase I
- 4.4.1. Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Phase II
- 4.5.1. Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Phase III
- 4.6.1. Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Phase IV
- 4.7.1. Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis

5.1. Neurology Clinical Trials Market, By Study Design: Segment Dashboard
5.2. Neurology Clinical Trials Market, By Study Design: Movement Analysis
5.3. Neurology Clinical Trials Market Estimates & Forecasts, By Study Design, 2018 - 2030 (USD Million)
5.4. Interventional
- 5.4.1. Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Observational
- 5.5.1. Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Expanded Access
- 5.6.1. Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis

6.1. Neurology Clinical Trials Market, By Indication: Segment Dashboard
6.2. Neurology Clinical Trials Market, By Indication: Movement Analysis
6.3. Neurology Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030 (USD Million)
6.4. Alzheimer's Disease
- 6.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Depression (MDD)
- 6.5.1. Depression (MDD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Parkinson's Disease (PD)
- 6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Epilepsy
- 6.7.1. Epilepsy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Stroke
- 6.8.1. Stroke Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Traumatic Brain Injury (TBI)
- 6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Amyotrophic Lateral Sclerosis (ALS)
- 6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.11. Huntington's Disease
- 6.11.1. Huntington's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.12. Muscle Regeneration
- 6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.13. Others
- 6.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

7.1. Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
7.2. Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
7.3. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2018 - 2030 (USD Million)
7.4. Alzheimer's Disease
- 7.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Alzheimer's Disease Interventional
  - 7.4.2.1. Alzheimer's Disease Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Alzheimer's Disease Observational
  - 7.4.3.1. Alzheimer's Disease Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Alzheimer's Disease Expanded Access
  - 7.4.4.1. Alzheimer's Disease Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Depression (MDD)
- 7.5.1. Depression (MDD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Depression (MDD) Interventional
  - 7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Depression (MDD) Observational
  - 7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. Depression (MDD) Expanded Access
  - 7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Parkinson's Disease (PD)
- 7.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Parkinson's Disease (PD) Interventional
  - 7.6.2.1. Parkinson's Disease (PD) Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Parkinson's Disease (PD) Observational
  - 7.6.3.1. Parkinson's Disease (PD) Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. Parkinson's Disease (PD) Expanded Access
  - 7.6.4.1. Parkinson's Disease (PD) Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Epilepsy
- 7.7.1. Epilepsy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Epilepsy Interventional
  - 7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Epilepsy Observational
  - 7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. Epilepsy Expanded Access
  - 7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Stroke
- 7.8.1. Stroke Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. Stroke Interventional
  - 7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Stroke Observational
  - 7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. Stroke Expanded Access
  - 7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.9. Traumatic Brain Injury (TBI)
- 7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.2. Traumatic Brain Injury (TBI) Interventional
  - 7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.3. Traumatic Brain Injury (TBI) Observational
  - 7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.4. Traumatic Brain Injury (TBI) Expanded Access
  - 7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.10. Amyotrophic Lateral Sclerosis (ALS)
- 7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
  - 7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
  - 7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
  - 7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.11. Huntington's Disease
- 7.11.1. Huntington's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.11.2. Huntington's Disease Interventional
  - 7.11.2.1. Huntington's Disease Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.11.3. Huntington's Disease Observational
  - 7.11.3.1. Huntington's Disease Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.11.4. Huntington's Disease Expanded Access
  - 7.11.4.1. Huntington's Disease Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.12. Muscle Regeneration
- 7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.12.2. Muscle Regeneration Interventional
  - 7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.12.3. Muscle Regeneration Observational
  - 7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.12.4. Muscle Regeneration Expanded Access
  - 7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.13. Others
- 7.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.13.2. Others Interventional
  - 7.13.2.1. Others Interventional Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.13.3. Others Observational
  - 7.13.3.1. Others Observational Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.13.4. Others Expanded Access
  - 7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis

8.1. Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
8.2. Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
8.3. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2018 - 2030 (USD Million)
8.4. Alzheimer's Disease
- 8.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. Alzheimer's Disease Phase I
  - 8.4.2.1. Alzheimer's Disease Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Alzheimer's Disease Phase II
  - 8.4.3.1. Alzheimer's Disease Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Alzheimer's Disease Phase III
  - 8.4.4.1. Alzheimer's Disease Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Alzheimer's Disease Phase IV
  - 8.4.5.1. Alzheimer's Disease Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Depression (MDD)
- 8.5.1. Depression (MDD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Depression (MDD) Phase I
  - 8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Depression (MDD) Phase II
  - 8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. Depression (MDD) Phase III
  - 8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Depression (MDD) Phase IV
  - 8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Parkinson's Disease (PD)
- 8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Parkinson's Disease (PD) Phase I
  - 8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Parkinson's Disease (PD) Phase II
  - 8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. Parkinson's Disease (PD) Phase III
  - 8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Parkinson's Disease (PD) Phase IV
  - 8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Epilepsy
- 8.7.1. Epilepsy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Epilepsy Phase I
  - 8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Epilepsy Phase II
  - 8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.4. Epilepsy Phase III
  - 8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.5. Epilepsy Phase IV
  - 8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Stroke
- 8.8.1. Stroke Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. Stroke Phase I
  - 8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Stroke Phase II
  - 8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. Stroke Phase III
  - 8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Stroke Phase IV
  - 8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.9. Traumatic Brain Injury (TBI)
- 8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.9.2. Traumatic Brain Injury (TBI) Phase I
  - 8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.9.3. Traumatic Brain Injury (TBI) Phase II
  - 8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.9.4. Traumatic Brain Injury (TBI) Phase III
  - 8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.9.5. Traumatic Brain Injury (TBI) Phase IV
  - 8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.10. Amyotrophic Lateral Sclerosis (ALS)
- 8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
  - 8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
  - 8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
  - 8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
  - 8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.11. Huntington's Disease
- 8.11.1. Huntington's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.11.2. Huntington's Disease Phase I
  - 8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.11.3. Huntington's Disease Phase II
  - 8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.11.4. Huntington's Disease Phase III
  - 8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.11.5. Huntington's Disease Phase IV
  - 8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.12. Muscle Regeneration
- 8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.12.2. Muscle Regeneration Phase I
  - 8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.12.3. Muscle Regeneration Phase II
  - 8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.12.4. Muscle Regeneration Phase III
  - 8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.12.5. Muscle Regeneration Phase IV
  - 8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.13. Others
- 8.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.13.2. Others Phase I
  - 8.13.2.1. Others Phase I Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.13.3. Others Phase II
  - 8.13.3.1. Others Phase II Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.13.4. Others Phase III
  - 8.13.4.1. Others Phase III Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.13.5. Others Phase IV
  - 8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis

9.1. Neurology Clinical Trials Market, By Value Chain: Segment Dashboard
9.2. Neurology Clinical Trials Market, By Value Chain: Movement Analysis
9.3. Neurology Clinical Trials Market Estimates & Forecasts, By Value Chain, 2018 - 2030 (USD Million)
9.4. In-house
- 9.4.1. In-house Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. CROs
- 9.5.1. CROs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Investigator Sites/Clinical Sites
- 9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis

10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2030
10.3. North America
- 10.3.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.3.2. U.S
  - 10.3.2.1. Key Country Dynamics
  - 10.3.2.2. Competitive Scenario
  - 10.3.2.3. Regulatory Framework
  - 10.3.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.3.3. Canada
  - 10.3.3.1. Key Country Dynamics
  - 10.3.3.2. Competitive Scenario
  - 10.3.3.3. Regulatory Framework
  - 10.3.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.3.4. Mexico
  - 10.3.4.1. Key Country Dynamics
  - 10.3.4.2. Competitive Scenario
  - 10.3.4.3. Regulatory Framework
  - 10.3.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4. Europe
- 10.4.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.2. UK
  - 10.4.2.1. Key Country Dynamics
  - 10.4.2.2. Competitive Scenario
  - 10.4.2.3. Regulatory Framework
  - 10.4.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.3. Germany
  - 10.4.3.1. Key Country Dynamics
  - 10.4.3.2. Competitive Scenario
  - 10.4.3.3. Regulatory Framework
  - 10.4.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.4. France
  - 10.4.4.1. Key Country Dynamics
  - 10.4.4.2. Competitive Scenario
  - 10.4.4.3. Regulatory Framework
  - 10.4.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.5. Italy
  - 10.4.5.1. Key Country Dynamics
  - 10.4.5.2. Competitive Scenario
  - 10.4.5.3. Regulatory Framework
  - 10.4.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.6. Spain
  - 10.4.6.1. Key Country Dynamics
  - 10.4.6.2. Competitive Scenario
  - 10.4.6.3. Regulatory Framework
  - 10.4.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.7. Denmark
  - 10.4.7.1. Key Country Dynamics
  - 10.4.7.2. Competitive Scenario
  - 10.4.7.3. Regulatory Framework
  - 10.4.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.8. Sweden
  - 10.4.8.1. Key Country Dynamics
  - 10.4.8.2. Competitive Scenario
  - 10.4.8.3. Regulatory Framework
  - 10.4.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.4.9. Norway
  - 10.4.9.1. Key Country Dynamics
  - 10.4.9.2. Competitive Scenario
  - 10.4.9.3. Regulatory Framework
  - 10.4.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5. Asia Pacific
- 10.5.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.2. Japan
  - 10.5.2.1. Key Country Dynamics
  - 10.5.2.2. Competitive Scenario
  - 10.5.2.3. Regulatory Framework
  - 10.5.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.3. China
  - 10.5.3.1. Key Country Dynamics
  - 10.5.3.2. Competitive Scenario
  - 10.5.3.3. Regulatory Framework
  - 10.5.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.4. India
  - 10.5.4.1. Key Country Dynamics
  - 10.5.4.2. Competitive Scenario
  - 10.5.4.3. Regulatory Framework
  - 10.5.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.5. Thailand
  - 10.5.5.1. Key Country Dynamics
  - 10.5.5.2. Competitive Scenario
  - 10.5.5.3. Regulatory Framework
  - 10.5.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.6. South Korea
  - 10.5.6.1. Key Country Dynamics
  - 10.5.6.2. Competitive Scenario
  - 10.5.6.3. Regulatory Framework
  - 10.5.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.5.7. Australia
  - 10.5.7.1. Key Country Dynamics
  - 10.5.7.2. Competitive Scenario
  - 10.5.7.3. Regulatory Framework
  - 10.5.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6. Latin America
- 10.6.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.6.2. Brazil
  - 10.6.2.1. Key Country Dynamics
  - 10.6.2.2. Competitive Scenario
  - 10.6.2.3. Regulatory Framework
  - 10.6.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.6.3. Argentina
  - 10.6.3.1. Key Country Dynamics
  - 10.6.3.2. Competitive Scenario
  - 10.6.3.3. Regulatory Framework
  - 10.6.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7. MEA
- 10.7.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.7.2. South Africa
  - 10.7.2.1. Key Country Dynamics
  - 10.7.2.2. Competitive Scenario
  - 10.7.2.3. Regulatory Framework
  - 10.7.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.7.3. Saudi Arabia
  - 10.7.3.1. Key Country Dynamics
  - 10.7.3.2. Competitive Scenario
  - 10.7.3.3. Regulatory Framework
  - 10.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.7.4. UAE
  - 10.7.4.1. Key Country Dynamics
  - 10.7.4.2. Competitive Scenario
  - 10.7.4.3. Regulatory Framework
  - 10.7.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 10.7.5. Kuwait
  - 10.7.5.1. Key Country Dynamics
  - 10.7.5.2. Competitive Scenario
  - 10.7.5.3. Regulatory Framework
  - 10.7.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)